Ocular Therapeutix Inc (OCUL)
6.17
+0.30
(+5.11%)
USD |
NASDAQ |
May 03, 16:00
6.16
-0.01
(-0.16%)
After-Hours: 20:00
Ocular Therapeutix Cash from Operations (Quarterly): -22.45M for Dec. 31, 2023
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -22.45M |
| September 30, 2023 | -7.732M |
| June 30, 2023 | -20.08M |
| March 31, 2023 | -19.97M |
| December 31, 2022 | -16.96M |
| September 30, 2022 | -13.17M |
| June 30, 2022 | -10.88M |
| March 31, 2022 | -18.60M |
| December 31, 2021 | -15.15M |
| September 30, 2021 | -12.98M |
| June 30, 2021 | -20.06M |
| March 31, 2021 | -17.36M |
| December 31, 2020 | -6.246M |
| September 30, 2020 | -13.66M |
| June 30, 2020 | -14.80M |
| March 31, 2020 | -18.85M |
| December 31, 2019 | -19.47M |
| September 30, 2019 | -19.54M |
| June 30, 2019 | -19.18M |
| March 31, 2019 | -19.39M |
| December 31, 2018 | -13.65M |
| September 30, 2018 | -10.87M |
| Date | Value |
|---|---|
| June 30, 2018 | -12.23M |
| March 31, 2018 | -12.47M |
| December 31, 2017 | -10.38M |
| September 30, 2017 | -14.38M |
| June 30, 2017 | -11.13M |
| March 31, 2017 | -14.58M |
| December 31, 2016 | -7.612M |
| September 30, 2016 | -7.331M |
| June 30, 2016 | -9.802M |
| March 31, 2016 | -9.256M |
| December 31, 2015 | -8.636M |
| September 30, 2015 | -9.70M |
| June 30, 2015 | -8.528M |
| March 31, 2015 | -6.879M |
| December 31, 2014 | -5.626M |
| September 30, 2014 | -6.333M |
| June 30, 2014 | -4.512M |
| March 31, 2014 | -4.025M |
| December 31, 2013 | -3.457M |
| September 30, 2013 | -2.85M |
| June 30, 2013 | -2.961M |
| March 31, 2013 | -3.377M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-22.45M
Minimum
Dec 2023
-6.246M
Maximum
Dec 2020
-16.16M
Average
-17.36M
Median
Mar 2021
Cash from Operations (Quarterly) Benchmarks
| Amgen Inc | 689.00M |
| Assertio Holdings Inc | 5.707M |
| CytomX Therapeutics Inc | -21.96M |
| EyePoint Pharmaceuticals Inc | -23.11M |
| Regeneron Pharmaceuticals Inc | 1.512B |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -0.459M |
| Cash from Financing (Quarterly) | 108.17M |
| Free Cash Flow | -76.32M |
| Free Cash Flow Per Share (Quarterly) | -0.2539 |
| Free Cash Flow to Equity (Quarterly) | -23.95M |
| Free Cash Flow Yield | -14.96% |